SCHEMBL9890771

SCHEMBL9890771

CNC(=O)Cc1cc(Cl)ccc1-c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SHMT1 P34896 1/20 0.47
CNR1 P21554 3/20 0.43
KCNA3 P22001 1/20 0.42
FABP4 P15090 3/20 0.42
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
FABP5 Q01469 1/20 0.40
GCGR P47871 3/20 0.39
P2RX1 P51575 1/20 0.39
TP53 P04637 2/20 0.38
THRB P10828 1/20 0.38
ANO1 Q5XXA6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890773 0.92 CNR1 (0.44) SHMT1CNR1KCNA3GCGRTP53
SCHEMBL2393668 0.88 KCNA5 (0.41) SHMT1
SCHEMBL9890728 0.86 FFAR1 (0.46) SHMT1CNR1
SCHEMBL9890782 0.85 PSEN1 (0.45) GCGRP2RX1
SCHEMBL3735666 0.82 FABP4 (0.45) SHMT1FABP4FABP5
SCHEMBL9890779 0.82 ALDH1A1 (0.44) ANO1
SCHEMBL9890770 0.81 ICMT (0.43) SHMT1KCNA3FABP4FABP5GCGR
SCHEMBL9892693 0.80 PTGDR2 (0.48) GCGRANO1
SCHEMBL2396004 0.80 FFAR1 (0.46)
SCHEMBL2391383 0.80 SLC6A4 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SHMT1 1479/4885CNR1 221/4885KCNA3 42/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 SHMT1 1479/4885CNR1 221/4885KCNA3 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.